SCHEMBL1327231

SCHEMBL1327231

CCc1cccc(CC)c1-c1cc(Cl)c(CN2C[C@@H](C)O[C@H](c3ccccc3)C2)c(C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 1/20 0.43
KDM4E B2RXH2 4/20 0.42
HTT P42858 1/20 0.42
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
ALDH1A1 P00352 2/20 0.36
GLA P06280 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
SLC2A1 P11166 2/20 0.34
C5AR1 P21730 2/20 0.33
CNR2 P34972 3/20 0.33
CD274 Q9NZQ7 2/20 0.32
PDCD1LG2 Q9BQ51 1/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1327923 0.86 CYP2A13 (0.35) CYP2A13KDM4EHTTSLC2A1C5AR1
SCHEMBL1329614 0.86 CYP2A13 (0.35) CYP2A13KDM4EHTTSLC2A1C5AR1
SCHEMBL1327281 0.84 C5AR1 (0.40) CYP2A13C5AR1SLC8A1
SCHEMBL1328774 0.80 CYP2A13 (0.46) CYP2A13KDM4EHTTTDP1MEN1
SCHEMBL4410376 0.77 CYP2A13 (0.44) CYP2A13KDM4EHTTTDP1MEN1
SCHEMBL2138632 0.76 CYP2A13 (0.42) CYP2A13KDM4EHTTTDP1ALDH1A1
SCHEMBL4410374 0.75 CYP2A13 (0.41) CYP2A13KDM4EHTTTDP1GAA
SCHEMBL1328168 0.74 CYP2A13 (0.43) CYP2A13KDM4EHTTTDP1MEN1
SCHEMBL1327167 0.74 CYP2A13 (0.41) CYP2A13KDM4EHTTTDP1ALDH1A1
SCHEMBL2141543 0.74 PDE10A (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES HUTCHINSON ALAN J (US) 2011-11-17 US disclosed
US-7863454-B2 3-substituted-6-aryl pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-01-04 US disclosed
US-20090176980-A1 3-Substituted-6-Aryl Pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2009-07-09 US disclosed
US-7342115-B2 Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology NEUROGEN CORPORATION (US) 2008-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES C3AR1, C5AR1, C5AR2 CYP2A13 1143/4885KDM4E 2088/4885HTT 4493/4885
US-20090176980-A1 3-Substituted-6-Aryl Pyridines C3AR1, C5AR1, C5AR2 CYP2A13 1143/4885KDM4E 2088/4885HTT 4493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.